Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia

• Published in: Journal of cancer education 2022-10, Vol.37 (5), p.1378-1384
• Main Authors: Dengina, Natalia, Chernykh, Marina, Degnin, Catherine, Chen, Yiyi, Tsimafeyeu, Ilya, Karaseva, Vera V., Tjulandin, Sergei, Laktionov, Konstantin, Thomas, Charles R., Mitin, Timur
• Format: Article
• Language: English
• Subjects: Barriers; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Chemotherapy; Clinical medicine; Education; Hospitals; Immunotherapy; Lung cancer; Oncology; Pharmacology/Toxicology; Radiation therapy; Simulation; Thoracic surgery
• ISSN: 0885-8195; 1543-0154
• DOI: 10.1007/s13187-021-01966-8

Background Definitive concurrent chemoradiation (cCRT) is offered to only 3% of Russian patients with stage III NSCLC. To determine the patterns of care and barriers to cCRT utilization in Russia, we conducted a survey of practicing radiation oncologists (ROs). Methods Electronic IRB-approved survey containing 15 questions was distributed to Russian ROs. Fisher’s exact test or Cochran-Armitage test of trend was used to assess the associations between clinical experience, practice type, and patterns of care. Results We analyzed 58 questionnaires completed by ROs—16 respondents from tertiary referral hospitals, and 42 from community or private centers. A total of 88% of respondents formulate treatment recommendations in multi-disciplinary tumor boards. For unresectable stage III NSCLC, the most common recommendation is sequential CRT (50%), followed by concurrent CRT (40%), with an observed higher utilization of cCRT in tertiary centers (9/16, 56% vs 14/42, 33%). Of the respondents, 31% do not offer cCRT to their pts. Among reasons for avoiding cCRT are (1) poor performance of pts (76%); (2) high toxicity of therapy (55%); (3) lack of consensus among tumor board members (33%); and (4) preference for sequential CRT (31%). Only 3% do not irradiate elective LNs. Eighty-six percent of respondents counsel their NSCLC pts regarding smoking cessation. Conclusions Despite level 1 evidence, cCRT is rarely used in Russia for pts with locally advanced NSCLC, and preference for sequential therapy and concerns over high toxicity are the most common barriers. Education of Russian ROs may increase cCRT utilization, leading to improved survival, notably in the era of maintenance immunotherapy.